New Delhi: The Serum Institute of India has sought approval for the emergency use of the Corona vaccine developed by it in India. The Serum Institute of India has also become the first Indian company to apply for emergency use of the vaccine with the Drug Controller General of India (DGCI). Before that, Pfizer has applied to the DGCI for emergency use of its vaccine in India. At the moment, it has now increased the possibility of using covid 19 vaccine in India soon.
According to the information, the Serum Institute of India has requested the DGCI to approve the ‘Covishield’ vaccine during the epidemic citing medical needs and the public interest at a wider scale. According to sources, the Serum Institute has cited its clinical trials during its application to the Drug Controller General of India. The Serum Institute has said that it has been reported from four data from clinical trials that the ‘Covishield’ vaccine has proved to be very effective in treating corona patients with severe symptoms. Two of the four test data relate to the UK while one to India and one to Brazil.
Recently, Adar Poonawala, CEO of Serum Institute of India, claimed that the corona vaccine proved to be up to 90 per cent effective in the ‘covishield’ test. It will be available to everyone soon. He also claimed that an agreement of 10 crore doses has been made with AstraZeneca. By January, Covishield’s minimum 10 million doses will be available, while by the end of February it will increase further. Recently, AstraZeneca has requested the World Health Organization to approve its emergency use in low-income countries.
